87 papers found
Refreshing results…
Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life: Lifelong prophylaxis in patients with haemophilia
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.
Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions: Quality of life improves in MDS patients treated for anaemia
Discordancy of Bypassing Therapy
Immune tolerance induction in patients with hemophilia A
Physical activity and joint function in adults with severe haemophilia on long-term prophylaxis:
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma
Genetic and Environmental Risk Factors for Inhibitor Development
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy: Research paper
Characterization of a Novel Aberrant Splice Site, 79bp Downstream of Exon 5 in the Human Factor 7 Gene Detected in Patients with Severe Congenital Factor VII Deficiency.
Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities.
Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V
Cost and outcome: Comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor
From Theory to Practice: Applying Current Clinical Knowledge and Treatment Strategies to the Care of Hemophilia A Patients With Inhibitors
Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr-ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy
Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome
Internal and External Determinants of Bleeding Patterns on Prophylaxis for Severe Haemophilia A.
Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.
Missing publications? Read more about our data sources.